Vincent Puard ^UDM

Dr. Vincent Puard, the co-founder and CEO of MAbSilico, holds a PhD in biology from CHRU Bretonneau and INRA Tours, along with a master's degree in biomedicines from the University of Tours. With a background that includes a post-doctoral fellowship at Avacta Life Sciences in the UK and various roles focusing on biomolecule development and cancer research, Vincent is well-versed in the field. In 2016, he co-founded MAbSilico, a TechBio company that leverages AI-based solutions for antibody drug design and discovery. Serving as CEO, Vincent has played a key role in the company's mission to provide computationally designed antibodies through AI, complemented by biological validations. MAbSilico assists biotech and pharma companies by delivering computational candidates within days, characterized in silico and validated using state-of-the-art biological technologies. The company utilizes 3D modeling, interaction simulation, and linear sequences analysis to define antibody drug candidates based on epitope, affinity, off-target risk, cross-species reactivity, and developability assessment, ensuring readiness for biological activity evaluation. NLP technologies are employed to gather information about antibodies and their targets from various databases, facilitating competitive landscape analysis and assessing the freedom to operate for computationally designed antibody candidates.